CIK 0000882095
- Large accelerated filer
GILEAD SCIENCES, INC.
Sign in to watch- Ticker
- GILD
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 943047598
- Phone
- +1 650-574-3000
- Business address
- 333 LAKESIDE DR, FOSTER CITY, CA, 94404
- Former names
- GILEAD SCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $36,996,096
- in 12 filings, $37.0M under 10b5-1 plans
Net −$36,996,096. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-31 | Dickinson Andrew D Chief Financial Officer | Option exercise 10b5-1 | +44,160 | $65.38 | $2.9M | 273,053 |
| 2025-01-31 | Dickinson Andrew D Chief Financial Officer | Sale 10b5-1 | −142,180 | $97.22 | $13.8M | 129,873 |
| 2025-01-31 | Dickinson Andrew D Chief Financial Officer | Option exercise · Non-qualified Stock Option (Right to Buy) 10b5-1 | −26,170 | 104,690 | ||
| 2025-01-31 | Dickinson Andrew D Chief Financial Officer | Option exercise · Non-qualified Stock Option (Right to Buy) 10b5-1 | −71,850 | 0 | ||
| 2025-01-31 | Dickinson Andrew D Chief Financial Officer | Option exercise · Non-qualified Stock Option (Right to Buy) 10b5-1 | −44,160 | 0 | ||
| 2025-01-25 | Telman Deborah H EVP, Corporate Affairs & GC | Option exercise | +515 | 21,827 | ||
| 2025-01-25 | Telman Deborah H EVP, Corporate Affairs & GC | Shares withheld for taxes | −187 | $93.07 | $17K | 21,640 |
| 2025-01-25 | Telman Deborah H EVP, Corporate Affairs & GC | Option exercise · Restricted Stock Unit | −515 | 27,879 | ||
| 2025-01-15 | Dickinson Andrew D Chief Financial Officer | Sale 10b5-1 | −2,500 | $91.35 | $228K | 129,873 |
| 2025-01-02 | Berger Dietmar Chief Medical Officer | Grant or award · Restricted Stock Unit | +48,975 | 48,975 | ||
| 2024-12-16 | Dickinson Andrew D Chief Financial Officer | Sale 10b5-1 | −8,500 | $91.96 | $782K | 132,373 |
| 2024-12-13 | Patterson Sandra SVP, Controllership | Option exercise | +157 | 37,533 | ||
| 2024-12-13 | Patterson Sandra SVP, Controllership | Shares withheld for taxes | −157 | $91.86 | $14K | 37,078 |
| 2024-12-13 | Patterson Sandra SVP, Controllership | Option exercise · Restricted Stock Unit | −157 | 11,827 | ||
| 2024-12-10 | Telman Deborah H EVP, Corporate Affairs & GC | Option exercise | +639 | 21,618 | ||
| 2024-12-10 | Telman Deborah H EVP, Corporate Affairs & GC | Shares withheld for taxes | −306 | $92.34 | $28K | 21,312 |
| 2024-12-10 | Telman Deborah H EVP, Corporate Affairs & GC | Option exercise · Restricted Stock Unit | −639 | 28,394 | ||
| 2024-12-10 | Patterson Sandra SVP, Controllership | Option exercise | +901 | 37,486 | ||
| 2024-12-10 | Patterson Sandra SVP, Controllership | Shares withheld for taxes | −408 | $92.34 | $38K | 37,078 |
| 2024-12-10 | Patterson Sandra SVP, Controllership | Option exercise · Restricted Stock Unit | −901 | 12,282 |
Page 21 of 30 · 599 trades